IndustryCompany release

Iridex cuts 2026 revenue guidance to $46-48M after 19% third-quarter sales drop

🇺🇸 Iridex Corp (IRIX) · Tue 17 Nov 2026

The glaucoma and retinal laser maker reported weaker European and Asian demand and is reviewing its product lines while shifting manufacturing to contract manufacturers.

Iridex, a US maker of laser systems for glaucoma and retinal disease, reported third-quarter 2026 revenue of $10.2M on 17 November, down from $12.5M a year earlier. The quarter ended on 3 October, and the figures represent a fall of about 19%.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on VigiEye and CompePharma
  • One subscription for both sites, cancel any time
Continue with Google
or
You'll be signed in straight away; we also email you a link to confirm your address. Reading every article takes a $4.99/month subscription (secure checkout by Stripe), billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. See our terms and privacy policy.

Company's press release (SEC filing): Iridex Corp ↗

Article written by VigiEye from the official source (Iridex Corp). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →